New Product - Zinbryta
Zinbryta (daclizumab) is a humanised IgG1 monoclonal antibody that binds specifically to the alpha subunit of the interleukin-2 receptor (IL-2Rα, CD25). Immunomodulatory effects of daclizumab are believed to reduce CNS pathology in multiple sclerosis and thereby reduce the occurrence of relapses and disability progression. Zinbryta is indicated for the treatment of relapsing forms of multiple sclerosis to delay the progression of physical disability and to reduce the frequency of relapse. Zinbryta is contraindicated in patients with pre-existing hepatic disease or hepatic impairment, including ALT or AST at least 2 times the ULN at baseline, because Zinbryta could exacerbate existing liver dysfunction; and a history of autoimmune hepatitis or other autoimmune condition involving the liver. Zinbryta is available as a 150 mg/mL prefilled pen in packs of 1’s.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629